Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma.

Andrews A, Warner K, Rodriguez-Ramirez C, Pearson AT, Nör F, Zhang Z, Kerk S, Kulkarni A, Helman JI, Brenner JC, Wicha MS, Wang S, Nör JE.

Clin Cancer Res. 2019 Mar 1;25(5):1588-1600. doi: 10.1158/1078-0432.CCR-17-2730. Epub 2018 Nov 29.

PMID:
30498096
2.

Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas.

Nör F, Warner KA, Zhang Z, Acasigua GA, Pearson AT, Kerk SA, Helman JI, Sant'Ana Filho M, Wang S, Nör JE.

Clin Cancer Res. 2017 Feb 15;23(4):1036-1048. doi: 10.1158/1078-0432.CCR-16-1235. Epub 2016 Aug 22.

3.

ALDH/CD44 identifies uniquely tumorigenic cancer stem cells in salivary gland mucoepidermoid carcinomas.

Adams A, Warner K, Pearson AT, Zhang Z, Kim HS, Mochizuki D, Basura G, Helman J, Mantesso A, Castilho RM, Wicha MS, Nör JE.

Oncotarget. 2015 Sep 29;6(29):26633-50. doi: 10.18632/oncotarget.5782.

4.

Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma.

Warner KA, Nör F, Acasigua GA, Martins MD, Zhang Z, McLean SA, Spector ME, Chepeha DB, Helman J, Wick MJ, Moskaluk CA, Castilho RM, Pearson AT, Wang S, Nör JE.

Clin Cancer Res. 2016 Jul 15;22(14):3550-9. doi: 10.1158/1078-0432.CCR-15-1698. Epub 2016 Mar 2.

5.

Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.

Shangary S, Ding K, Qiu S, Nikolovska-Coleska Z, Bauer JA, Liu M, Wang G, Lu Y, McEachern D, Bernard D, Bradford CR, Carey TE, Wang S.

Mol Cancer Ther. 2008 Jun;7(6):1533-42. doi: 10.1158/1535-7163.MCT-08-0140.

6.

A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis and sensitizes lung cancer cells to chemotherapy.

Sun SH, Zheng M, Ding K, Wang S, Sun Y.

Cancer Biol Ther. 2008 Jun;7(6):845-52. Epub 2008 Mar 5.

PMID:
18340116
7.

MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.

Feng FY, Zhang Y, Kothari V, Evans JR, Jackson WC, Chen W, Johnson SB, Luczak C, Wang S, Hamstra DA.

Neoplasia. 2016 Apr;18(4):213-22. doi: 10.1016/j.neo.2016.01.006.

8.

Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.

Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, Konopleva M, Andreeff M, Rassidakis GZ.

Clin Cancer Res. 2007 Jun 1;13(11):3380-7.

9.

Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer.

Nör C, Zhang Z, Warner KA, Bernardi L, Visioli F, Helman JI, Roesler R, Nör JE.

Neoplasia. 2014 Feb;16(2):137-46. doi: 10.1593/neo.131744.

10.

Efficacy of MDM2 inhibitor MI-219 against lung cancer cells alone or in combination with MDM2 knockdown, a XIAP inhibitor or etoposide.

Zheng M, Yang J, Xu X, Sebolt JT, Wang S, Sun Y.

Anticancer Res. 2010 Sep;30(9):3321-31.

PMID:
20944104
11.

Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma.

Mochizuki D, Adams A, Warner KA, Zhang Z, Pearson AT, Misawa K, McLean SA, Wolf GT, Nör JE.

Oncotarget. 2015 Sep 8;6(26):22822-35.

12.

Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy.

Azmi AS, Philip PA, Aboukameel A, Wang Z, Banerjee S, Zafar SF, Goustin AS, Almhanna K, Yang D, Sarkar FH, Mohammad RM.

Curr Cancer Drug Targets. 2010 May;10(3):319-31.

13.

Inhibition of the p53-MDM2 interaction by adenovirus delivery of ribosomal protein L23 stabilizes p53 and induces cell cycle arrest and apoptosis in gastric cancer.

Zhang Y, Shi Y, Li X, Du W, Luo G, Gou Y, Wang X, Guo X, Liu J, Ding J, Wu K, Fan D.

J Gene Med. 2010 Feb;12(2):147-56. doi: 10.1002/jgm.1424.

PMID:
20020415
14.

SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.

Wang S, Sun W, Zhao Y, McEachern D, Meaux I, Barrière C, Stuckey JA, Meagher JL, Bai L, Liu L, Hoffman-Luca CG, Lu J, Shangary S, Yu S, Bernard D, Aguilar A, Dos-Santos O, Besret L, Guerif S, Pannier P, Gorge-Bernat D, Debussche L.

Cancer Res. 2014 Oct 15;74(20):5855-65. doi: 10.1158/0008-5472.CAN-14-0799. Epub 2014 Aug 21.

15.

Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells.

Krishnamurthy S, Dong Z, Vodopyanov D, Imai A, Helman JI, Prince ME, Wicha MS, Nör JE.

Cancer Res. 2010 Dec 1;70(23):9969-78. doi: 10.1158/0008-5472.CAN-10-1712. Epub 2010 Nov 23.

16.

Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.

Hai J, Sakashita S, Allo G, Ludkovski O, Ng C, Shepherd FA, Tsao MS.

J Thorac Oncol. 2015 Aug;10(8):1172-80. doi: 10.1097/JTO.0000000000000584.

17.

MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.

Canner JA, Sobo M, Ball S, Hutzen B, DeAngelis S, Willis W, Studebaker AW, Ding K, Wang S, Yang D, Lin J.

Br J Cancer. 2009 Sep 1;101(5):774-81. doi: 10.1038/sj.bjc.6605199.

18.

A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma.

Yi H, Yan X, Luo Q, Yuan L, Li B, Pan W, Zhang L, Chen H, Wang J, Zhang Y, Zhai Y, Qiu MZ, Yang DJ.

J Exp Clin Cancer Res. 2018 May 2;37(1):97. doi: 10.1186/s13046-018-0765-8.

19.

SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.

Bill KL, Garnett J, Meaux I, Ma X, Creighton CJ, Bolshakov S, Barriere C, Debussche L, Lazar AJ, Prudner BC, Casadei L, Braggio D, Lopez G, Zewdu A, Bid H, Lev D, Pollock RE.

Clin Cancer Res. 2016 Mar 1;22(5):1150-60. doi: 10.1158/1078-0432.CCR-15-1522. Epub 2015 Oct 16.

20.

Characterization of tumorigenic cell lines from the recurrence and lymph node metastasis of a human salivary mucoepidermoid carcinoma.

Warner KA, Adams A, Bernardi L, Nor C, Finkel KA, Zhang Z, McLean SA, Helman J, Wolf GT, Divi V, Queimado L, Kaye FJ, Castilho RM, Nör JE.

Oral Oncol. 2013 Nov;49(11):1059-66. doi: 10.1016/j.oraloncology.2013.08.004. Epub 2013 Sep 12.

Supplemental Content

Support Center